Skip to content

Celldex Therapeutics CLDX Change in Other Liabilities

Change in Other Liabilities at other companies

Pfizer logo
PfizerPFE
-$916.75M-17.7%
Amgen logo
AmgenAMGN
-$75M+3.8%
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
-$493K-694%

Other financials

Income statement

See full
Revenue$15.0K-97.8%
Operating income-$84.4M-34.6%
Net income-$78.7M-46.3%
EPS (diluted)-$1.18-45.7%

Balance sheet

See full
Cash & equivalents$35.7M+109%
Total debt$1.9M-44.3%
Total equity$456.2M-35.1%
Total assets$511.3M-30.9%

Cash flow

See full
Operating cash flow-$65.6M-20.6%
CapEx$1.6M+518%
Free cash flow-$67.2M-23.0%

Valuation

See full
Market cap$2.65B+75.2%

Profitability

See full
Operating margin-35,688.5%-39,114pp
Net margin-32,753.6%-35,519pp
FCF margin-26,125.8%-28,907pp

Returns & leverage

See full
Return on equity-48.9%-498pp
Debt / equity0.0×
Current ratio8.9×-12.7×

Where this comes from

Reported directly by Celldex Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherOperatingLiabilities.

The official record: Celldex Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Celldex Therapeutics's change in other liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Celldex Therapeutics's change in other liabilities?
Celldex Therapeutics (CLDX) reported change in other liabilities of -$1.36M in Q1 2026.
How has Celldex Therapeutics's change in other liabilities changed year-over-year?
Celldex Therapeutics's change in other liabilities decreased by 124.8% year-over-year, from -$604K to -$1.36M.
What does change in other liabilities mean?
Change in miscellaneous liabilities affecting operating cash flow.